Loading...
The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE) W trial showed that warfarin therapy was superior to clopidogrel plus aspirin for patients with atrial fibrillation who have at least one stroke risk factor (JW Neurol Sep 6 2006). Now, the same research group report results of the international ACTIVE A study, comparing aspirin plus placebo with aspirin plus clopidogrel for stroke prevention in patients with atrial fibrillation and at least one stroke risk factor who were considered “not suitable” for warfarin therapy.
A total of 7554 patients were randomized to receive 75 mg of clopidogrel or placebo daily, in addition to aspirin (75–100 mg daily), for a median of 3.6 years. The primary out…